R2 Capital Strategies, LLC’s Biogen BIIB Stock Holding History

R2 Capital Strategies, LLC’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$223K	Buy	+1,030	New	+$197K	0.1%	113

Other funds holding BIIB

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

ADEF

Adams Diversified Equity Fund Baltimore, Maryland $3.27B AUM 45.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

BPC

Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

R2 Capital Strategies, LLC's BIIB Position: Q2 2026 in Review

R2 Capital Strategies, LLC opened a new position in Biogen (BIIB) in Q2 2026: 1,030 shares worth $223K. The stake represents 0.1% of the portfolio and ranks #113 among its holdings.

269 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

R2 Capital Strategies, LLC held 1,030 shares of Biogen worth $223K as of Q2 2026.
Biogen was a new R2 Capital Strategies, LLC position in Q2 2026.
Biogen made up 0.1% of R2 Capital Strategies, LLC's portfolio in Q2 2026, its #113 holding.
269 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on R2 Capital Strategies, LLC's 13F filing for Q2 2026, filed 23 Jul 2026.